Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters

Inhibition of human liver microsomal CYP by nateglinide

(2015) Toshiyuki Takanohashi et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Impact of OATP transporters on pharmacokinetics

(2009) A Kalliokoski et al.   BRITISH JOURNAL OF PHARMACOLOGY

The effect ofSLCO1B1polymorphism on repaglinide pharmacokinetics persists over a wide dose range

(2008) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs

(2008) Kazuya Maeda et al.   Drug Metabolism and Pharmacokinetics

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

(2008) Annikka Kalliokoski et al.   Pharmacogenetics and Genomics